Vascular endothelial growth factor gene polymorphism prevalence in patients with diabetic macular oedema and its correlation with anti-vascular endothelial growth factor treatment outcomes

Clinical and Experimental Ophthalmology

Volumn 42, Issue 4, 2014, Pages 369-378

  El Shazly, Sherien F ^a   El Bradey, Mohamed H ^a   Tameesh, Mohamed K ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Bevacizumab; DMO; PCR REFLP; Polymorphism; VEGF

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BODY MASS; CENTRAL MACULAR THICKNESS; CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETIC MACULAR EDEMA; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIET RESTRICTION; DNA ISOLATION; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PROLIFERATIVE RETINOPATHY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETINA MACULA EDEMA; TREATMENT OUTCOME; VISUAL ACUITY;

BEVACIZUMAB; DMO; PCR-REFLP; POLYMORPHISM.; VEGF;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; GENOTYPING TECHNIQUES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84901695741     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/ceo.12182     Document Type: Article

References (39)

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-321.
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14.
3. Joanne W, Sophie L, Kawasaki R etal. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012; 35: 3556-3564.
4. Ishida S, Usui T, Yamashiro K, Kaji Y, Ahmed E, Carrasquillo KG. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003; 44: 2155-2162.
5. Chiarelli F, Spagnoli A, Basciani F. Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with type 1 diabetes mellitus. Relation to glycaemic control and microvascular complications. Diabetes Med 2000; 17: 650-656.
6. Funatsu H, I Yamashita H, Sakata K etal. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 2005; 112: 806-816.
7. Petrovic MG, Korosec P, Kosnik M etal. Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy. Mol Vis 2008; 14: 1382-1387.
8. Vincenti V, Cassano C, Rocchi M, Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996; 93: 1493-1495.
9. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV. Novel polymorphisms in the promoter and 5'UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 1999; 60: 1245-1249.
10. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003; 63: 812-816.
11. Watson CJ, Webb NJA, Bottomley MJ, Renchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 2000; 12: 1232-1235.
12. Awata T, Inoue K, Kurihara S etal. A common polymorphism in the 5-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002; 51: 1635-1639.
13. Awata T, Susumu K, Nobuki T etal. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem Biophys Res Commun 2005; 333: 679-685.
14. Mojca G, Peter K, Košnik J etal. Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy. Mol Vis 2008; 14: 1382-1387.
15. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signaling- in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-371.
16. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331-335.
17. Arevalo JF, Sanchez JG, Wu L etal.; Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 2009; 116: 1488-1497.
18. Kloeckener-Gruissem B, Barthelmes D, Labs S etal. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest Ophthalmol Vis Sci 2011; 52: 4694-4702.
19. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 26: S5-20.
20. Maquar FX, Giller P, Bernar JF, Mante TP, Borel JP. A method specifically measuring hemoglobin A1C with disposable commercial ion exchange column. Clin Chem Acta 1980; 108: 329-332.
21. Richmonds W. Determination of serum Cholesterol. Clin Chem 1970; 19: 1350-1356.
22. Fossati P, Prenciphe L. Determination of serum triglycerides. Clin Chem 1982; 28: 207-210.
23. Lopes-Virella MF, Stone S, Ellis S, Collwell JA. Cholesterol determination in high density lipoprotein separated by three different method. Clin Chem 1977; 23: 882-884.
24. Friedewalde WT, Levy RI, Freddrickson DS. Estimation of the concentration of LDL cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
25. World medical association declaration of Helsinki. Recommendation guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925-926.
26. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study reports no 1. Arch Ophthalmol 1985; 103: 1796-1806.
27. Holladay JT. Proper method for calculating average visual acuity. J Refract Surg 1997; 13: 388-391.
28. Petrie A, Sabin C. Medical Statistics at A Glance, 2nd edn. London: Blackwell, 2005; 144-152.
29. Suganthalakshmi B, Anand R, Kim R etal. Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol Vis 2006; 12: 336-341.
30. Funatsu H, Yamashita H, Noma H, Mimura T, Sakata K, Hori S. Risk evaluation of outcome of vitreous surgery for proliferative diabetic retinopathy based on vitreous level of vascular endothelial growth factor and angiotensin II. Br J Ophthalmol 2004; 88: 1064-1068.
31. Aiello LP, Avery RL, Arrigg PG etal. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
32. Watanabe D, Suzuma K, Suzuma I etal. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2005; 139: 476-481.
33. Lambrechts D, Storkebaum E, Morimoto M etal. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003; 34: 383-394.
34. Boiardi L, Casali B, Nicoli D etal. Vascular endothelial growth factor gene polymorphisms in giant cell arteritis. J Rheumatol 2003; 30: 2160-2164.
35. Young HS, Summers AM, Bhushan M, Brenchley PE, Griffiths CE. Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol 2004; 122: 209-215.
36. Salvarani C, Boiardi L, Casali B, Olivieri I, Cantini F. Vascular endothelial growth factor gene polymorphisms in Behcet's disease. J Rheumatol 2004; 31: 1785-1789.
37. Vannay A, Dunai G, Banyasz I etal. Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity. Pediatr Res 2005; 57: 396-398.
38. Huez I, Bornes S, Bresson D, Creancier L, Prats H. New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation. Mol Endocrinol 2001; 15: 2197-2210.
39. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW etal. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114: 1860-1867.